The merger of CVS Health, one of the nation’s largest pharmacy retailers, with third-largest health insurer Aetna has the potential to transform the health care system and raises concerns about the effect the merger could have on drug prices and competition. This would be the first time that a large pharmacy retailer gains control of one of the nation’s largest health insurers. CVS Health not only has 9,800 retail outlets in nearly every state (except Wyoming), but also 94 million members in pharmacy benefit manager CVS/Caremark. Continue reading
Alzheimer’s disease is the sixth leading cause of death in the U.S. Despite decades of research, there’s still no cure, and few options to slow or minimize symptoms. The last Alzheimer’s drug was approved more than 15 years ago, but a new campaign, called Disrupting Dementia, hopes to drive new diagnostics and treatments while also supporting patients and families affected by this devastating condition.
Despite efforts to curb the use of antipsychotic drugs in nursing homes, about 20 percent of residents – more than 250,000 vulnerable individuals – are still given these potent medications, according to a new report from the Long Term Care Community Coalition (LTCCC).
While the Centers for Medicare and Medicaid (CMS) estimates that only a very small percentage of the senior population will ever have a condition warranting use of these powerful medications, psychotropic drugs still are being overused among the elderly, especially for those suffering from dementia, the report concluded. Continue reading
Health journalists in Washington, D.C., participated in an all-day training session about reporting on the opioid crisis, hearing from treatment experts, medical providers and public health advocates.
The event took place Feb. 23 at the University of Maryland’s Philip Merrill College of Journalism, and was a partnership between the D.C. chapter of the Association of Health Care Journalists and the National Press Foundation. Continue reading
Public Citizen’s Health Research Group today released an updated report cataloging all major financial settlements that the pharmaceutical industry has been forced to sign with federal and state governments from 1991 through 2017 for illegal activities.
The report shows a dramatic decrease since 2013 in both the total amount paid and the average penalty. Additionally, it found that state governments have virtually stopped prosecuting pharmaceutical manufacturers on their own initiative and with their own resources. Continue reading
Taken at face value, Right-to-Try (RTT) legislation sounds like a no-brainer, promising to improve access to treatments yet unapproved for marketing by the FDA for people with terminal illnesses. But it’s not that simple, according to Alison Bateman-House, Ph.D., M.P.H., M.A., an ethicist and assistant professor at the New York University School of Medicine.
In fact, many of its basic provisions make it unlikely to deliver on its promise. At a New York City Metro AHCJ Chapter meeting in November, she discussed reasons for her argument that RTT will only serve to limit, rather than expand, access to potentially life-saving treatments. Continue reading